Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells

• Published in: International journal of nanomedicine Vol. 16; pp. 5437 - 5449
• Main Authors: Park, June Yong, Shin, Yuseon, Won, Woong Roeck, Lim, Chaemin, Kim, Jae Chang, Kang, Kioh, Husni, Patihul, Lee, Eun Seong, Youn, Yu Seok, Oh, Kyung Taek
• Format: Journal Article
• Language: English
• Published: Macclesfield Taylor & Francis Ltd 01.01.2021; Dove; Dove Medical Press
• Subjects: Cancer; Cholesterol; circulating tumor cell; Cytotoxicity; Lipids; liposome; Medical prognosis; Metastasis; metastatic tumor; Nanoparticles; Original Research; Particle size; Peptides; Polyethylene glycol; Spectrum analysis; tumor-targeting ligand; Tumors; urokinase-type plasminogen activator; United States > US; South Korea
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S315619

Purpose: An AE147 peptide-conjugated nanocarrier based on PEGylated liposomes was developed in order to target the metastatic tumors overexpressing urokinase-type plasminogen activator receptor (uPAR), which cancer progression via uPA signaling. Therefore, the AE147 peptide-conjugated nanocarrier system may hold the potential for active targeting of metastatic tumors. Methods: The AE147 peptide, an antagonist of uPAR, was conjugated to the PEGylated liposomes for targeting metastatic tumors overexpressing uPAR. Docetaxel (DTX), an anticancer drug, was incorporated into the nanocarriers. The structure of the AE147-conjugated nanocarrier, its physicochemical properties, and in vivo biodistribution were evaluated. Results: The DTX-loaded nanocarrier showed a spherical structure, a high drug-loading capacity, and a high colloidal stability. Drug carrying AE147 conjugates were actively taken up by the uPAR-overexpressing MDA-MB-231 cancer cells. In vivo animal imaging confirmed that the AE147-conjugated nanoparticles effectively accumulated at the sites of tumor metastasis. Conclusion: The AE147-nanocarrier showed potential for targeting metastatic tumor cells overexpressing uPAR and as a nanomedicine platform for theragnosis applications. These results suggest that this novel nano-platform will facilitate further advancements in cancer therapy.